KRAS to the future; plus ARPA-H & EGFR: a BioCentury podcast
FDA’s approval of Amgen’s Lumakras represents so much more than the authorization of the first inhibitor again KRAS, once thought to be an “undruggable” target. In BioCentury’s latest podcast, BioCentury’s editors discuss how the target went from hard-to-drug to market and what the impact the KRAS G12C inhibitor could have for patients. They also discuss Zai’s deal for a rival KRAS inhibitor, the Biden administration’s ARPA-H initiative and what to expect from EGFR data at ASCO21.
Senior Editor Lauren Martz and Editor in Chief Simone Fishburn discuss why the approval of Lumakras sotorasib from Amgen Inc. (NASDAQ:AMGN) is so significant for the biotech industry and how Amgen and other companies have developed programs against KRAS so quickly.
Fishburn also explains why the approval was a “sentimental” one for many who have watched the journey of ras biology. “It’s a target that’s been known for so long. It probably was the first one to get the moniker of undruggable, which it obviously is not,” she said. “I think a lot of people really see this as a signature moment.”